<DOC>
	<DOCNO>NCT00382187</DOCNO>
	<brief_summary>The present study aim evaluate safety immunogenicity two dos , administer three week apart , 6 month booster dose , two influenza vaccine contain 7.5 microgram 15 microgram H5N1 influenza antigen , non-adjuvanted influenza vaccine contain 15 microgram H5N1 influenza antigen , adult</brief_summary>
	<brief_title>Safety Immunogenicity Two Adjuvanted One Non-adjuvanted H5N1 Influenza Vaccine Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Male female volunteer 1860 year age Any autoimmune disease serious acute , chronic progressive disease Hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component vaccine History neurological symptom sign , anaphylactic shock follow administration vaccine Within past 7 day , experience acute disease infection require systemic antibiotic antiviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>influenza</keyword>
	<keyword>pandemic influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>adjuvanted influenza vaccine</keyword>
	<keyword>H5N1 influenza antigen</keyword>
	<keyword>MF59</keyword>
	<keyword>Pandemic influenza disease</keyword>
</DOC>